SportsoneSource媒体2007年10月25日报道：Deckers户外运动公司第三季度销售收入为1.294亿美元，相比去年的0.823亿美元涨幅达57.2 ％。摊薄后每股收益为1.47美元，相比去年的81美分增涨了81.5 ％。UGG销售额为1.137亿美元，增长67.5 ％; Teva的销售额同比增长12.1 ％ ，达1120万美元。Simple品牌的销售与去年持平，为440万美元

　　部分摘要

　　UGG

　　UGG品牌第三季度尽销售收入为1.137亿美元，相比2006年第三季度0.679亿美元增长了67.5 ％。，消费者对整个产品线，包括鞋子、拖鞋，临时的、男士产品、儿童产品，以及新的高端时装系列产品的消费需求，在全球范围内不断增长，这种旺盛的消费需求也刺激了国内的销售。

　　Teva

　　Teva品牌网第三季度尽销售收入1120万美元，与去年同期的1000万美元增长了12.1 ％。

　　Simple

　　Simple品牌的净销售额在2007年第三季度和2006年第三季度均为440万美元，持平。

　　2007年全年展望

　　公司目前将把2007年全年收入增长目标调整为2006年的39％以上， 而先前制订的目标大约是35％。

　　公司目前将把2007年全年摊薄后每股盈余增长目标调整为2006年的35 ％ ，而先前制订的目标大约是25％。

　　第四季度展望

　　相比2006年第四季度，公司将其2007年第四季度的营收目标提升至2006年同期的35％，摊薄后每股收益目标提升为15％。而之前的预期目标分别为30％和10％。

 　　原文：Deckers Q3 Sales Jump 57% on UGG Strength

　　SportsOneSource Media     Posted: 10/25/2007

　　Deckers Outdoor Corp. saw a 57.2% jump in third quarter sales to $129.4 million from $82.3 million last year. Diluted EPS increased 81.5% to $1.47 from 81 cents, as restated, and ahead of previous guidance of approximately $1.20. UGG sales increased 67.5% to $113.7 million; Teva‘s increased 12.1% to $11.2 million. Simple sales were flat at $4.4 million.

　　Angel Martinez, president and CEO, said, “Our record third quarter performance was driven by strong full price selling of UGG brand product throughout the United States coupled with growing demand for the brand overseas. Consumer reaction to the UGG brand’s fall line has been extremely favorable which we believe underscores the progress we have made evolving the product offering, increasing the breadth and depth of each collection and enhancing the brand‘s image as the leader in luxury comfort. In addition, our sUCCess at penetrating new geographic regions, increasing shelf space and broadening our target market also contributed to our better than expected results. We move forward with positive momentum in our business, a solid infrastructure to support our growth objectives both domestically and overseas, and a long-term strategic development plan designed to maximize the opportunities for each of our leading brands.”

　　Segment Summary

　　UGG

　　UGG Brand net sales for the third quarter increased 67.5% to $113.7 million compared to $67.9 million in the third quarter of 2006. Domestic sales were fueled by robust consumer demand for the entire product line, including boots, slippers, casuals, men’s, kids‘, and the new high-end fashion collection, coupled with strong international growth.

　　Teva

　　Teva Brand net sales for the third quarter increased 12.1% to $11.2 million compared to $10.0 million for the same period last year. Teva’s results were driven by increased sell-through for sandals as well as the positive reaction to the brand‘s expanded closed-toe product offering.

　　Simple

　　Simple Brand net sales were $4.4 million for both the third quarter of 2007 and the third quarter of 2006. Simple’s performance was negatively impacted by shipping delays for ecoSNEAKS as a result of production issues, which have been resolved. Despite this, ecoSNEAKS was said to have had a “very solid debut” across multiple channels of distribution, while Green Toe was successful in opening more mainstream accounts this fall.

　　Consumer Direct

　　Sales for the Consumer Direct business, which are included in the brand sales numbers above, increased 82.3% to $10.6 million compared to $5.8 million for the same period a year ago, mostly due to an increase in UGG Brand internet sales. In addition, results for the third quarter of 2007 included sales from the company‘s UGG Brand flagship store in New York City and two retail outlet stores in Riverhead and Woodbury Common, New York, which were not in operation in the third quarter of 2006.

　　Full-Year 2007 Outlook

　　The company is increasing its 2007 full year revenue growth target to approximately 39% over 2006, up from previous guidance of approximately 35%.

　　The company is increasing its 2007 full year diluted earnings per share growth target to approximately 35% over 2006 before the restatement adjustments as disclosed in the company’s Form 10-K/A for the year ended December 31, 2006 and the $15.3 million pre-tax impairment loss attributable to our Teva trademark that was recorded in the fourth quarter of 2006, up from previous guidance of approximately 25%.

　　Fiscal 2007 guidance includes approximately $5.3 million of stock compensation expense, an increase of $3.2 million over 2006, and approximately $2.4 million of expenses related to the investigation and restatement of the company‘s consolidated financial statements.

　　Fourth Quarter Outlook

　　The company is also increasing its fourth quarter 2007 revenue target to approximately 35% and its diluted earnings per share target to approximately 15% compared to the fourth quarter of 2006, before the restatement adjustment and impairment charge. This is up from its previous revenue and diluted earnings per share growth targets of 30% and 10%, respectively.